Hospital News and Research

RSS

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

StemCells, Inc. (NASDAQ:STEM) announced today that it will soon initiate with the University of California, San Francisco (UCSF) Children’s Hospital a Phase I clinical trial to evaluate the therapeutic potential of StemCells’ proprietary HuCNS-SC® product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that primarily affects infants and young children.

10 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

Capsule launches new Enterprise Medical Device Connectivity Solution

Capsule (www.capsuletech.com), the leading provider of medical device connectivity, today announces the release of their new Enterprise Medical Device Connectivity Solution enabled by the Capsule Neuron™.

10 Sep 2009

St. Vincent develops the first-ever HIV educational widget

Saint Vincent Catholic Medical Centers and the New York State Department of Health (DOH) today unveiled a novel Web-based technology to rapidly instruct health care providers throughout New York State about HIV diagnosis and prevention.

10 Sep 2009

Health care reform should tackle food safety

Linda Rivera’s excruciating case of food poisoning (Severe Case Gives Context to Issue of Food Safety Washington Post 9/1/09) should shine some light on a crucial reality that is missing from most health care reform plans: you can’t fix America’s health care unless you provide Americans with a safe food supply.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

ValiMed chosen for Geisinger Medical Center's Medication Safety Program

CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) -- Worldwide studies show that high-risk medication compounding errors in pharmacies continue to cause significant harm to patients and economic loss to hospitals. Geisinger Medical Center joins a growing list of world-class hospitals that are proactively addressing this issue by selecting the ValiMed™ Medication Safety System to assure the "Right Drug at the Right Dose" every time.

10 Sep 2009

Concerro's CommandAware hospital incident management system enhanced with location-based intelligence tool

San Diego-based Concerro, Inc., the market leader in enterprise-wide hospital shift and disaster workforce management software, has enhanced its CommandAware® hospital incident management system by adding a new location-based intelligence tool to help clients identify and interact with regional data in a more efficient way.

10 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

Second-quarter fiscal 2009 results announced by Streamline Health Solutions

Streamline Health Solutions, Inc. (Nasdaq: STRM) today announced financial results for the second quarter and six months, ended July 31, 2009.

10 Sep 2009

PDR merges with Health Care Notification Network

The iconic Physicians' Desk Reference (PDR®) found in every physician's office, clinic and hospital is merging with the Health Care Notification Network (HCNN), the only network that delivers FDA-required drug Alerts to physicians and other prescribers online.

From Physicians' Desk Reference (PDR) 10 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Cancer Research UK launches a new Cancer Centre at Cardiff

Cardiff today (Thursday) joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

10 Sep 2009

Complete Genomics sequences and delivers 14 human genomes

Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009.

10 Sep 2009

Symposium on innovations in health care experience to be hosted

The Mayo Clinic Center for Innovation will host Transform, a collaborative symposium on innovations in health care experience and delivery, Sept. 13-15, http://centerforinnovation.mayo.edu/transform. Transform will feature nationally recognized speakers discussing topics focused on innovation methodology and innovations in health care delivery models, including Web-based tools.

10 Sep 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

Lack of awareness in aged men reagarding prostate cancer treatment options

Prostate cancer remains one of the most commonly diagnosed cancers in the United States. In fact, one in six men will develop prostate cancer. It is also the second-leading cause of cancer death in the United States. But a recent survey suggests that many men at risk for the cancer still aren't aware of all available treatment options.

10 Sep 2009

New protocol to tackle postpartum depression

Up to 80 percent of women experience depressive symptoms postpartum, with one in eight reporting the emergence of major depression within weeks of delivery.

10 Sep 2009

New form of malarial infection identified

Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. The research, funded by the Wellcome Trust, confirms the potentially deadly nature of the disease.

10 Sep 2009

New type of stem cell in the prostate may be a source for prostate cancer, say researchers

A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study by researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.

10 Sep 2009